Other Routes of Protein and Peptide Delivery: Transdermal, Topical, Uterine, and Rectal - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 657

[23] Weaver JC, Vaughan TE, Chizmadzhev Y. Theory of electrical creation of aqueous path-
ways across skin transport barriers. Adv Drug Deliv Rev 1999;35:21-39.
[24] Jadoul A, Bouwstra J, Preat V. Effect of iontophoresis and electroporation on the stratum
corneum. Adv Drug Deliv Rev 1999;35:89-105.
[25] Prausnitz MR. A practical assessment of transdermal drug delivery by skin electropora-
tion. Adv Drug Deliv Rev 1999;35:61-7.
[26] Chizmadzhev YA, Zarnitsin VG, Weaver JC, Potts RO. Mechanism of electroinduced
ionic species transport through a multilamellar lipid system. Biophys J 1995;68:749-65.
[27] Pliquett UF, Gusbeth CA. Perturbation of human skin due to application of high voltages.
Bioelectrochemistry 2000;51:41-51.
[28] Pliquett UF, Vanbever R, Preat V, Weaver JC. Local transport regions (LTRs) in human
stratum corneum due to long and short “high voltage” pulses. Bioelectrochem Bioenerg
1998;47:151-61.
[29] Pliquett UF, Weaver JC. Electroporation of human skin: simultaneous measurement of
changes in the transport of two fluorescent molecules and in the passive electrical prop-
erties. Bioelectrochem Bioenerg 1996;39:1-12.
[30] Preat V, Vanbever R. In vivo efficacy and safety of skin electroporation. Adv Drug Deliv
Rev 1999;35:77-88.
[31] Heller R, Gilbert R, Jaroszeski MJ. Clinical applications of electrochemotherapy. Adv
Drug Deliv Rev 1999;35:119-29.
[32] Denet A, Préat V. Transdermal delivery of timolol by electroporation through human
skin. J Control Release 2003;88:253-62.
[33] Green PG. Iontophoretic delivery of peptide drugs. J Control Release 1996;41:33-48.
[34] Burnette RR, Ongpipattanakul B. Characterization of the permselective properties of
excised human skin during iontophoresis. J Pharm Sci 1987;76:765-73.
[35] Guy RH, Kalia YN, Delgado-Charro MB, Merino V, Lopez A, Marro D. Iontophoresis:
electrorepulsion and electroosmosis. J Control Release 2000;64:129-32.
[36] Green PG, Hinz RS, Kim A, Szoka Jr FC, Guy RH. Iontophoretic delivery of a series of
tripeptides across the skin in-vitro . Pharm Res 1991;8:1121-7.
[37] Oldenburg K, Vo KT, Smith GA, Selick HE. Iontophoretic delivery of oligonucleotides
across full thickness hairless mouse skin. J Pharm Sci 1995;84:915-21.
[38] Heit MC, McFarland A, Bock R, Riviere JE. Isoelectric focusing and capillary zone elec-
trophoretic studies using luteinizing hormone releasing hormone and its analog. J Pharm
Sci 1994;83:654-6.
[39] Hirvonen J, Guy RH. Transdermal iontophoresis: modulation of electroosmosis by poly-
peptides. J Control Release 1998;50:283-89.
[40] Hoogstraate AJ, Srinivasan V, Sims SM, Higuchi WI. Iontophoretic enhancement of pep-
tides: behaviour of leuprolide versus model permeants. J Control Release 1994;31:41-7.
[41] Delgadocharro MB, Rodriguezbayon AM, Guy RH. Iontophoresis of nafarelin: effects
of current density and concentration on electrotransport in vitro . J Control Release
1995;35:35-40.
[42] Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. Adv Drug Deliv Rev
2004;56:619-58.
[43] Lattin GA, Padmanabhan RV, Phis JB. Electronic control of iontophoretic drug delivery.
Ann N Y Acad Sci 1991;618:450-64.
[44] Pikal MJ. The role of electroosmotic flow in transdermal iontophoresis. Adv Drug Deliv
Rev 1992;9:201-37.
[45] Santi P, Guy RH. Reverse iontophoresis—parameters determining electroosmotic flow. I.
PH and ionic strength. J Control Release 1996;38:159-65.